Updates are available Correction dated 2022-07-12
Click to view Correction: https://doi.org/10.1038/s41698-022-00293-5
-
Authors
Hoge, Anna C. H.
Getz, Michal
Zimmer, Anat
Ko, Minjeong
Raz, Linoy
Beroukhim, Rameen
Golub, Todd R.
Ha, Gavin http://orcid.org/0000-0001-7578-7272
Ben-David, Uri http://orcid.org/0000-0001-7098-2378
- License Information
-
More Information
Article History
Received: 9 July 2021
Accepted: 22 March 2022
First Online: 28 April 2022
Change Date: 12 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41698-022-00293-5
Competing Interests
: T.R.G. is a consultant to GlaxoSmithKline and is a founder of Sherlock Biosciences. R.B. own shares in Ampressa and receives grant funding from Novartis. U.B.-D. receives grant funding from Novocure. The other authors declare no competing interests.
